MAP2K7 and ductal breast carcinoma in situ: This potentially suggests that the observed differential drug efficacy of inhibitors (PI3K and MEK inhibitors) is independent of underlying pathway mutation and rather transcriptional and post-transcriptional mechanisms are likely to play a role in rendering the advanced cancer cells (DCIS) more aggressive and less responsive to therapies.